In Silico Design of a Trans-Amplifying RNA-Based Vaccine Against SARS-CoV-2 Structural Proteins

Overview

Journal Adv Virol

Publisher Wiley

Specialty Microbiology

Date 2024 Oct 9

PMID 39380944

Authors

Fatemeh Nafian

Ghazal Soleymani

Zahra Pourmanouchehri

Mahnaz Kiyanjam

Simin Nafian

Sayed Mohammad Mohammadi

Hanie Jeyroudi

Sharareh Berenji Jalaei

Fatemeh Sabzpoushan

Affiliations

Soon will be listed here.

Abstract

Nucleic acid-based vaccines allow scalable, rapid, and cell-free vaccine production in response to an emerging disease such as the current COVID-19 pandemic. Here, we objected to the design of a multiepitope mRNA vaccine against the structural proteins of SARS-CoV-2. Through an immunoinformatic approach, promising epitopes were predicted for the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Fragments rich in overlapping epitopes were selected based on binding affinities with HLA classes I and II for the specific presentation to B and T lymphocytes. Two constructs were designed by fusing the fragments in different arrangements via GG linkers. Construct 1 showed better structural properties and interactions with toll-like receptor 2 (TLR-2), TLR-3, and TLR-4 during molecular docking and dynamic simulation. A 50S ribosomal L7/L12 adjuvant was added to its N-terminus to improve stability and immunogenicity. The final RNA sequence was used to design a trans-amplifying RNA (taRNA) vaccine in a split-vector system. It consists of two molecules: a nonreplicating RNA encoding a trans-acting replicase to amplify the second one, a trans-replicon (TR) RNA encoding the vaccine protein. Overall, the immune response simulation detected that activated B and T lymphocytes and increased memory cell formation. Macrophages and dendritic cells proliferated continuously, and IFN- and cytokines like IL-2 were released highly.

References

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz L, Vormehr M . COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses. Nature. 2020; 586(7830):594-599. DOI: 10.1038/s41586-020-2814-7. View

Burley S, Bhikadiya C, Bi C, Bittrich S, Chen L, Crichlow G . RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res. 2020; 49(D1):D437-D451. PMC: 7779003. DOI: 10.1093/nar/gkaa1038. View

Mukherjee S . Toll-like receptor 4 in COVID-19: friend or foe?. Future Virol. 2022; . PMC: 9017673. DOI: 10.2217/fvl-2021-0249. View

Desta I, Porter K, Xia B, Kozakov D, Vajda S . Performance and Its Limits in Rigid Body Protein-Protein Docking. Structure. 2020; 28(9):1071-1081.e3. PMC: 7484347. DOI: 10.1016/j.str.2020.06.006. View

Samad A, Ahammad F, Nain Z, Alam R, Imon R, Hasan M . Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach. J Biomol Struct Dyn. 2020; 40(1):14-30. PMC: 7441805. DOI: 10.1080/07391102.2020.1792347. View

Cai X, Li J, Liu T, Brian O, Li J . Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. Brief Funct Genomics. 2021; 20(5):289-303. PMC: 8194884. DOI: 10.1093/bfgp/elab027. View

Khan A, Khan T, Ali S, Aftab S, Wang Y, Qiankun W . SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines. Biomed Pharmacother. 2021; 143:112176. PMC: 8433040. DOI: 10.1016/j.biopha.2021.112176. View

Mo C, Li X, Wu Q, Fan Y, Liu D, Zhu Y . SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses. Vaccine. 2023; 41(46):6863-6869. DOI: 10.1016/j.vaccine.2023.09.059. View

Castiglione F, Mantile F, De Berardinis P, Prisco A . How the interval between prime and boost injection affects the immune response in a computational model of the immune system. Comput Math Methods Med. 2012; 2012:842329. PMC: 3446774. DOI: 10.1155/2012/842329. View

10.

Lokman S, Rasheduzzaman M, Salauddin A, Barua R, Tanzina A, Rumi M . Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: A computational biology approach. Infect Genet Evol. 2020; 84:104389. PMC: 7266584. DOI: 10.1016/j.meegid.2020.104389. View

11.

Ruch T, Machamer C . The coronavirus E protein: assembly and beyond. Viruses. 2012; 4(3):363-82. PMC: 3347032. DOI: 10.3390/v4030363. View

12.

Mukherjee S, Bhattacharyya D, Bhunia A . Host-membrane interacting interface of the SARS coronavirus envelope protein: Immense functional potential of C-terminal domain. Biophys Chem. 2020; 266:106452. PMC: 7418743. DOI: 10.1016/j.bpc.2020.106452. View

13.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

14.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

15.

Ballesteros-Briones M, Silva-Pilipich N, Herrador-Canete G, Vanrell L, Smerdou C . A new generation of vaccines based on alphavirus self-amplifying RNA. Curr Opin Virol. 2020; 44:145-153. PMC: 7474593. DOI: 10.1016/j.coviro.2020.08.003. View

16.

Herrera N, Morano N, Celikgil A, Georgiev G, Malonis R, Lee J . Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega. 2021; 6(1):85-102. PMC: 7771249. DOI: 10.1021/acsomega.0c03512. View

17.

Zheng W, Zhang C, Li Y, Pearce R, Bell E, Zhang Y . Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell Rep Methods. 2021; 1(3). PMC: 8336924. DOI: 10.1016/j.crmeth.2021.100014. View

18.

Larsen J, Lund O, Nielsen M . Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2:2. PMC: 1479323. DOI: 10.1186/1745-7580-2-2. View

19.

Chandra Das N, Sen Gupta P, Panda S, Rana M, Mukherjee S . Reverse vaccinology assisted design of a novel multi-epitope vaccine to target Wuchereria bancrofti cystatin: An immunoinformatics approach. Int Immunopharmacol. 2022; 115:109639. DOI: 10.1016/j.intimp.2022.109639. View

20.

Yadav R, Chaudhary J, Jain N, Kumar Chaudhary P, Khanra S, Dhamija P . Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19. Cells. 2021; 10(4). PMC: 8067447. DOI: 10.3390/cells10040821. View